Arbutus Biopharma (ABUS) vs Aura Biosciences (AURA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Aura Biosciences (AURA) has outperformed Arbutus Biopharma (ABUS) over the past year, gaining 12.2% versus a gain of 0.0%. Aura Biosciences is the larger company by market cap ($669.9 million vs $657.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABUS | AURA |
|---|---|---|
| Share price | $4.29 | $6.46 |
| Market cap | $657.55M | $669.93M |
| 1-day change | -4.24% | +4.70% |
| YTD return | -10.81% | +18.53% |
| 1-year return | 0.00% | +12.15% |
| 5-year return | +5.15% | — |
| P/E ratio (TTM) | 5.64 | — |
| EPS (TTM) | $0.76 | $-1.83 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.45 | $9.54 |
| 52-week low | $3.50 | $4.73 |
| Distance from 52-week high | -21.28% | -32.25% |
| Analyst consensus | none | none |
| Avg. price target upside | +24.71% | +156.97% |
| Average volume | 4.68M | 748.04K |
| Shares outstanding | 153.28M | 103.70M |
| Employees | 19 | 113 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AURA has outperformed ABUS by 12.2 percentage points over the past year.
About Arbutus Biopharma
ABUS stock →Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1.
Healthcare · Biotechnology · 19 employees
About Aura Biosciences
AURA stock →Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
Healthcare · Biotechnology · 113 employees
ABUS vs AURA FAQ
Which is bigger, Arbutus Biopharma or Aura Biosciences?
Aura Biosciences (AURA) is larger, with a market capitalization of $669.93M compared with $657.55M for Arbutus Biopharma (ABUS).
Which stock has performed better over the past year, ABUS or AURA?
AURA returned +12.15% over the past 12 months, compared with 0.00% for ABUS (price return, excluding dividends). Past performance does not predict future results.
Are Arbutus Biopharma and Aura Biosciences in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.